The General Medical Services (GMS), Drug Payment (DP) and Long-Term Illness (LTI) schemes 1 made up 98.6% of the 68.3m community drug items prescribed in 2010. Prescribing rates refer to the number of drug items prescribed per person and averaged 14.9 items in Ireland in 2010, ranging from 13.2 in the East region to 17.1 in the South-East. We examined why regional prescribing rates under the GMS, DP and LTI community drug schemes differ.
Introduction
The Irish Government has cumulatively reduced real public consumption by almost 16% since the onset of recession in 2008; a further small decline of 0.7% is estimated for 2013 2 .
Reducing non-capital public health spending (€13.3bn in 2012) 3 has been particularly difficult. Primary Care (Medical Card Services) Scheme spending was €2.5bn in 2012 4 .
Despite the HSE negotiating an 11% reduction in the unit cost of scheme medicines between 2008 and 2010 recession swelled the number covered by the GMS scheme by 9%, eroding all but 2% of the negotiated cost saving 5 .
In 2010 a total of 68.3m community drug scheme (GMS, DP and LTI) items were prescribed, averaging 14.87 items per person in Ireland. Regional APRs (average prescribing rates) per person covered ranged from 13.17 in the East to 17.09 in the South-East and display considerable regional variations (see Figure 1 and Table A1 in Appendix).
Figure 1
Prescribing rate variations impact the regional cost of public medicines. For example, in 2010 GMS medicines cost €625.85 per person covered in the North-West & Donegal but were over a third more, €841.55, per person covered, in the Midlands. To date, these regional differences 6 have attracted little research attention.
This paper focuses solely on documenting the scale and tracing the sources of differences in regional prescribing rates 7 , that is, on why, when suitably scaled, the size and composition of regional medicine baskets differ. We show how each region's mapped epidemiological health profile, its scheme coverage rates and national prescribing rate norms impact regional prescribing rates. We identify those regions whose scheme prescribing intensities differ significantly from national norms, having controlled for other factors.
Methods
In 2010 24 therapeutic main groups of medicines accounted for 80% of the 68.3m community drug (i.e. GMS, DP and LTI scheme) items prescribed in Ireland. We extracted the national prescribing rates (i.e. scheme items/scheme population) for these 24 groups from the PCRS database. We aggregated the 24 national prescribing rates into 6 main WHO/ATC We used KL regional health index values to construct expected prescribing rates (EPRs) for each ATC category in each region. We did this by adjusting the national per capita actual prescribing rate (APR) or national norm for each ATC category of drugs (given in Table A1) pro rata with each region's KL health index value, which measures the regional-to-national prevalence of the main health conditions for which that ATC therapeutic group of drugs was prescribed.
6 Sub-regional Local Health Office (LHO) cost variations are even more striking. were similarly constructed for the DP and LTI schemes in the Midlands.
The exercise was repeated for the remaining 7 regions, yielding 24 regional EPRs -one under each of the 3 community drug schemes in each of the 8 regions.
The Midlands GMS actual prescribing rate (APR) is the number of GMS items prescribed in the Midlands divided by its GMS population: APRs were similarly defined and computed for the DP and the LTI drug scheme. This exercise was also repeated in the remaining 7 regions, yielding 24 total APRs -one for each of the 3 community drug schemes in each of the 8 regions.
Coverage rates under the community drug scheme vary widely between regions (see Table   A1 ). 10 Persons ineligible for the GMS the LTI schemes are eligible for the DP scheme. Some DP prescribing falls below the DP claims threshold and is not claimed. This imparts a slight downward bias to DP prescribing ratesbut not to publicly sub-vented prescriptions. We also ran augmented versions of equation (3) by including binary dummy variables to test if significant systematic departures of actual from expected prescribing rates occurred in specific regions or schemes.
Where (i)
Finally, we also tested whether regional health status alone could account for regional prescribing variations. We constructed scheme-independent EPRs for each of the r regions from the product of (i) the national prescribing rate and (ii) region ' rshealth index value (e.g. 
Results
The model was estimated by OLS and the results are presented in Table 1 , is well determined and is insignificantly different from 1. Hence, scheme dependent EPRs, in general, yield unbiased estimators that track regional APRs with high precision.
The model was augmented by adding scheme and region specific binary variables and reestimated. The augmented model estimation results show that the GMS scheme prescribing rate in the North-West region is significantly less than expected, given its health status, its scheme coverage rates and national prescribing norms i.e. its GMS population was prescribed 8.56 fewer items than expected (about 25% fewer than the 33.68 item national GMS norm).
In contrast the South region LTI population was, on average, prescribed 11.54 more items than expected (about 55% more than the 20.81 item national LTI prescribing norm), given its health status, scheme coverage rates and national prescribing norms. The augmented model fit is This indicates that health status alone cannot explain prescribing rates. Community drug scheme (GMS, DP and LTI) coverage rates embed prescribing effects that cannot be purged when measuring EPRs without serious misspecification and virtual complete loss of explanatory power. Accordingly, we conclude that regional health status and regional drug scheme coverage jointly condition regional prescribing rates, with the two exceptions noted above.
Equation 1 measures each region's EPR, given its health status, scheme coverage rates and national prescribing norms. A region's total expected prescribing frequency is the product its EPR and its population (equation 2); hence, it allows us to simulate how the total number of prescribed items in each region and nationally is expected to respond to contemporaneous changes in health status and scheme coverage rates. These simulations (see Table A3 ) indicate that a 1 percentage point gain in health status in each ATC category and in each region would reduce community drug prescriptions in Ireland by 683,028 items. In contrast, reducing the GMS population uniformly by 1 percentage point in each region (that is, by 16,158 persons or 1% of the 1,615,809 person GMS-eligible population in 2010) and increasing the DP population by the same number would reduce expected prescribing by approximately 1,350,000 items. Hence, the number of community drug items prescribed nationally responds twice as elastically to changes in GMS coverage vis-à-vis its response to changes in population health status.
11 11 We applied 2010 national prescribing norms in making the above estimates. However, as the regional data show, GMS prescribing rates tend to increase as GMS coverage falls. Hence, our estimates are conservative. Table A3 ) identity how much each region is affected by these policy changes which largely reflects its demographics, health status and scheme coverage rates.
The simulations (in
The populous East region is most affected: less populous regions are less affected, the precise amount varying with their elderly population share, initial health status and community drug scheme coverage rates.
The simulations also identity which types of drugs are most affected by the policy changes.
Cardiovascular and "Other" 12 ATC drugs make up around half of all drug scheme baskets (see Figure 2 ) and account for 387,206 items (56.69%) of the total 683,028 item reduction that follows a uniform 1 percentage point health gain. The simulated outcomes from the 1 percentage point (that is, 16,158 person) reduction in GMS cardholders nets off the additional items they consume when they gain DP cover and it incorporates the minor compositional changes the DP scheme has on the therapeutic group items prescribed. basket has the highest proportion of 'Nervous System' items; the DP has the highest proportion of 'Other' items. These basket shares change over time but as Table A4 shows they change slowly and imply that simulations over short horizons are robust. 
Discussion and Conclusions
Regional health status, community drug scheme coverage rates and national prescribing norms jointly condition and explain around 92% of prescribing frequency variations in Irish regions and across Irish community drug schemes.
Having controlled for health status, scheme coverage rates and prescribing norms we find that the GMS prescribing rates in the North West is around 25% below the national GMS norm and the LTI prescribing rate in the Southern region is 55% above the national LTI prescribing norm.
We find that the semi-elasticity of the total number of community drug items prescribed nationally with respect to GMS coverage is twice as large as the semi-elasticity with respect to health status.
Our simulations also identify the therapeutic drug groups into which the simulated changes in prescribed items fall.
GMS, DP and LTI prescribing norms and drugs baskets (items per person covered) differ in size. The GMS basket is 62% larger than the LTI basket and it dwarfs the DP basket -it is 763% larger than it. That proportionality is broadly similar for different therapeutic drug groups and it changes slowly. 14 The lack of regional PCRS data prevents us from constructing separate APRs for each of the 6 ATC categories in each of the 8 regions, which would scale up sample size up 6-fold and enable testing of how well the EPR model explains regional prescribing rates in each of the 6 ATC drug categories. 
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